You are here

  • Home
  • Archive
  • Volume 66, Issue 6
  • Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease

Article Text

Article menu
Download PDFPDF
Letters
Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease
  1. Srilakshmi M Sharma1,
  2. Athimalaipet V Ramanan2,
  3. Philip Riley2,
  4. Andrew D Dick1
  1. 1University Department of Ophthalmology, Bristol Eye Hospital, UK
  2. 2North Bristol NHS Trust and Royal National Hospital for Rheumatic Diseases, Bath, UK
  1. Correspondence to:
    Dr S M Sharma
    Casey Eye Institute, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA; s_m_sharma{at}yahoo.com

https://doi.org/10.1136/ard.2006.065441

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    There is an identified disparity between the efficacy of tumour necrosis factor (TNF) inhibition in the treatment of uveitis in paediatric onset inflammatory arthritis and that of joint disease.1–,5

    We retrospectively reviewed the case notes of six patients with aggressive, refractory joint and ocular paediatric-onset disease treated with infliximab in a multidisciplinary clinic. Our report uses the Standardised Uveitis Nomenclature (SUN) grading system6 for uveitis and steroid dose as an outcome measure. All patients received weekly infliximab infusions at 0, 2, 6 and 8 weeks.

    Patients were maintained on low dose immunosuppression with methotrexate while receiving treatment. Five of six patients had previously been treated with another anti-TNF agent …

    View Full Text

    Footnotes

    • Published Online First 14 December 2006

    • Competing interests: None declared.